These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17565155)

  • 41. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
    Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
    Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
    Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
    PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model.
    Boreddy SR; Srivastava SK
    Oncogene; 2013 Aug; 32(34):3980-91. PubMed ID: 22986522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ηypoxia-inducible factor-1α, von Hippel-Lindau protein, and heat shock protein expression in ophthalmic pterygium and normal conjunctiva.
    Pagoulatos D; Pharmakakis N; Lakoumentas J; Assimakopoulou M
    Mol Vis; 2014; 20():441-57. PubMed ID: 24715760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice.
    Kang HW; Kim JM; Cha MY; Jung HC; Song IS; Kim JS
    Dig Dis Sci; 2012 Nov; 57(11):2873-82. PubMed ID: 22623043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
    Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
    Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization.
    Liu YV; Semenza GL
    Cell Cycle; 2007 Mar; 6(6):656-9. PubMed ID: 17361105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo.
    Sarkar S; Dutta D; Samanta SK; Bhattacharya K; Pal BC; Li J; Datta K; Mandal C; Mandal C
    Int J Cancer; 2013 Feb; 132(3):695-706. PubMed ID: 22729780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1α-VEGF signaling axis.
    Kim BK; Kim BR; Lee HJ; Lee SA; Kim BJ; Kim H; Won YS; Shon WJ; Lee NR; Inn KS; Kim BJ
    Biomaterials; 2014 Mar; 35(9):2924-33. PubMed ID: 24411674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
    Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
    J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
    Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
    J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization.
    Katschinski DM; Le L; Schindler SG; Thomas T; Voss AK; Wenger RH
    Cell Physiol Biochem; 2004; 14(4-6):351-60. PubMed ID: 15319539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.
    Baba Y; Fujii M; Maeda T; Suzuki A; Yuzawa S; Kato Y
    Biomed Res Int; 2015; 2015():657179. PubMed ID: 26075254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
    Yang YL; Ji C; Bi ZG; Lu CC; Wang R; Gu B; Cheng L
    PLoS One; 2013; 8(1):e54736. PubMed ID: 23372762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors.
    Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J
    Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
    Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
    Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.